Drugs / YK-029A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05767866 | Mar 2018 → Dec 2023 | — | Suzhou Puhe Pharmaceutical Technology Co., LTD | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05767892 | May 2023 → Jul 2025 overdue | non-small cell lung carcinoma | Suzhou Puhe Pharmaceutical Technology Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YK-029A | “The drug being tested in this study is called YK-029A.” NCT05767892 ↗ |
| Action | Inhibit | “a third-generation EGFR tyrosine kinase inhibitor” PMID 37776953 ↗ Sep 2023 |
| Route | Oral | “YK-029A was orally administered” PMID 37776953 ↗ Sep 2023 |
| Target | EGFR | “a third-generation EGFR tyrosine kinase inhibitor” PMID 37776953 ↗ Sep 2023 |